STING1 and neoplasm: SR‐717, a non‐nucleoside STING agonist, has been proven that it could significantly inhibit tumor growth, prevent metastasis, induce the presentation of tumor molecules to the immune system, and strongly increase the levels of CD8+ T cells and NK cells around the tumor [12].